Oocyte Cryopreservation Comparing Fresh and Vitrified Sibling Oocytes
Completed
Conditions studied: Infertility
In brief
Vitrification is a method to cryopreserve biological specimens that are sensitive to chilling injury such as oocytes and embryos, and it has been employed with increased survival rate and live births (Hong et al., 1999; Kuleshova et al., 1999; Yoon et al., 2000; Chung et al 2000; Wu et al., 2001: Kuwayama et al 2006). In their study the researchers propose to directly compare oocyte survival, fertilizaton and embryo development between sibling oocytes. The Cryotop method of vitrification, which the researchers aim to investigate in their study, has been reported as the most efficient method for human oocytes cryopreservation (Kuwayama et al, 2005, Antinori et al, 2006, Lucena et al, 2006, Cobo et al, 2008). Follow up of over 200 infants conceived from vitrified oocytes (Chian et al, 2008) indicate that the mean birth weight and the incidence of congenital anomalies are comparable to that of spontaneous conceptions in fertile women or infertile women undergoing IVF treatment.
Key facts
- Study ID
- NCT00986687
- Run by
- UConn Health
- People needed
- 17
- Starts
- 2009-08-01
- Expected to finish
- 2013-02-01
- Last updated by the study team
- 2015-12-03
Who can join
Age: 21 and older, up to 37. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Females 21 to 37 years of age.
- Normal serum follicle stimulating hormone (FSH) concentration <10 mIU/ml and estradiol (E2) concentration <70 pg/ml obtained on day #2 or 3 of the menstrual cycle.
- BMI < 35.
- No physical or gynecological abnormalities (including major uterine surgery) constituting a medical contraindication to embryo transfer and pregnancy including any known significant genetic disorders
- Non-smoker for at least 3 months prior to study enrollment.
- Normal antral follicle count (total ≥ 10).
You may not qualify if…
- Greater than 1 previous miscarriage.
- More than 1 previous failed IVF attempt.
- Previous poor response to ovarian stimulation (peak E2 level <1,000 pg/ml or < 4 oocytes retrieved).
- Presence of untreated hydrosalpinx.
- Stage III or IV endometriosis.
- Intent to have preimplantation genetic diagnosis (PGD) of embryos
- Unwillingness to freeze or inseminate all eligible oocytes or embryos.
- Male partner requiring surgical sperm retrieval (MESA or TESA).
Where it is running
- The Center for Advanced Reproductive Services — Farmington, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.